Results 81 to 90 of about 761 (100)

Inflammatory bowel disease treatment: Mechanisms to clinical translation (Review). [PDF]

Int J Mol Med
Tang S, Gou G, Liu Y, Wang F, Shu F, Deng Y, Zhang T, Xu J, Xie R.   +8 more
europepmc   +1 more source

The Cardiovascular Effects of Inflammatory Bowel Disease Therapy with Biologics and Small Molecules: A Comprehensive Review. [PDF]

J Clin Med
Mastoridou EM, Fousekis FS, Sakellariou XM, Mpakogiannis K, Nikas DN, Michalis LK, Katsanos KH, Milionis H.   +7 more
europepmc   +1 more source

Etrasimod Corticosteroid-Free Efficacy, Impact of Concomitant Corticosteroids on Efficacy and Safety, and Corticosteroid-Sparing Effect in Ulcerative Colitis: Analyses of the ELEVATE UC Clinical Program. [PDF]

J Crohns Colitis
Sands BE, Leung Y, Rubin DT, Gecse KB, Panés J, Goetsch M, Wang W, Woolcott JC, Smith CC, Wosik K, Schreiber S.   +10 more
europepmc   +1 more source

Switching Between Anti-TNFs and Other Biologic Drugs in Paediatric Inflammatory Bowel Disease: A Narrative Review and Practical Clinical Guide. [PDF]

J Inflamm Res
Romano A, Vazzana GF, Romano C.
europepmc   +1 more source

Correction to: Health-Related Quality of Life Outcomes With Etrasimod Treatment in Patients With Ulcerative Colitis: A Post Hoc Analysis of Data From ELEVATE UC 52 and ELEVATE UC 12. [PDF]

Inflamm Bowel Dis
europepmc   +1 more source

Oral Small-Molecule Therapies Versus Biologic Agents in Moderate-to-Severe Ulcerative Colitis: A Systematic Review of Pivotal Phase 3 Trials. [PDF]

Cureus
Zulfiqar O, Ali T, Mohayy Ud Din G, Babar ZUD, Zarif S.   +4 more
europepmc   +1 more source

Body Mass Index Did Not Affect Efficacy and Safety of Etrasimod: A Post Hoc Analysis of the ELEVATE Ulcerative Colitis Clinical Program. [PDF]

Am J Gastroenterol
Yarur AJ, Long MD, Torres J, Nandi N, Cross RK, Abbatemarco AM, Blanco D, Niezychowski W, Crosby C, Wu J, Pradeep G, Goetsch M, Panaccione R.   +12 more
europepmc   +1 more source

Etrasimod for moderate to severe ulcerative colitis. [PDF]

Aust Prescr
europepmc   +1 more source

Long-term Safety and Efficacy of Etrasimod for Ulcerative Colitis: Results from the Open-label Extension of the OASIS Study

Journal of Crohn's and Colitis, 2021
BACKGROUND AND AIMS: Etrasimod is an oral, selective, sphingosine 1-phosphate receptor modulator. In a phase 2, randomised, double-blind, placebo-controlled trial in adults with moderately-to-severely active ulcerative colitis [OASIS], etrasimod 2 mg ...
Bruce Sands, Severine Vermeire, Michael Chiorean   +2 more
exaly   +2 more sources